European Network for Cell Imaging and Tracking Expertise
Public support
Provider
Ministry of Education, Youth and Sports
Programme
—
Call for proposals
FP7-HEALTH-2007-A
Main participants
—
Contest type
RP - Co-financing of EC programme
Contract ID
1085/2011-32
Alternative language
Project name in Czech
European Network for Cell Imaging and Tracking Expertise
Annotation in Czech
Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an ?active drug? 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and clinical studies, however, success rates have been variable and clinical benefits have been limited. A majorissue is the fact that the mechanisms by which cell therapy works in the different disease areas, are still poorly understood. The ability to non-invasively monitor the fate and modes of action of transplanted cells over time is mandatory. The development of relevant imaging tools will lead to a better understanding of how cell therapy works, the possibility of response monitoring in patients, and sufficient safety of the treatment.. ENCITE will provide tools to allow this by developing; New imagin
Scientific branches
R&D category
AP - Applied research
CEP classification - main branch
FP - Other medical fields
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
EB - Genetics and molecular biology
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
10603 - Genetics and heredity (medical genetics to be 3)<br>10604 - Reproductive biology (medical aspects to be 3)<br>10605 - Developmental biology<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30101 - Human genetics<br>30106 - Anatomy and morphology (plant science to be 1.6)<br>30107 - Medicinal chemistry<br>30108 - Toxicology<br>30109 - Pathology<br>30221 - Critical care medicine and Emergency medicine<br>30223 - Anaesthesiology<br>30224 - Radiology, nuclear medicine and medical imaging<br>30225 - Allergy<br>30226 - Rheumatology<br>30227 - Geriatrics and gerontology<br>30229 - Integrative and complementary medicine (alternative practice systems)<br>30230 - Other clinical medicine subjects<br>30307 - Nursing<br>30308 - Nutrition, Dietetics<br>30309 - Tropical medicine<br>30310 - Parasitology<br>30311 - Medical ethics<br>30312 - Substance abuse<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>30501 - Forensic science<br>30502 - Other medical science<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider.
Solution timeline
Realization period - beginning
Jun 1, 2008
Realization period - end
May 31, 2012
Project status
U - Finished project
Latest support payment
Mar 15, 2012
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP13-MSM-7E-U/01:1
Data delivery date
Jun 28, 2013
Finance
Total approved costs
3,951 thou. CZK
Public financial support
3,951 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK